Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized…
19,730$
-5,19%
Echtzeit-Aktienkurs Hims & Hers Health Inc.
Bid:
Ask:
Nachrichten zur Hims & Hers Health Inc. Aktie
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized…
Hims & Hers Health, Inc. (HIMS) Stock Forecasts
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage…
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.69, marking a +1.24% move from the…
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.69, marking a +1.24% move from the…
Teladoc Soars 26% as Revenue and Profit Beat Estimates; Hims & Hers Health and American Well Tick Up
Shrinking revenue hasn’t kept Teladoc Health (NYSE:TDOC) from beating estimates on both sales and earnings. Early signs that its BetterHelp…
Hims & Hers Health, Inc. (HIMS) Seasonal Returns Chart
Hims & Hers Health, Inc. (HIMS) seasonal returns chart provides the mean and median returns by month to inform your…
HIMS November 2, 2026 Lead Plaintiff Deadline - Robbins LLP Reminds Investors About the Opportunity to Lead the Class Action Lawsuit
The complaint alleges that Hims & Hers Health shared private customer information with advertising platforms and engaged in deceptive…
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims…
Hims & Hers Health (HIMS) Alert: Securities Class Action Pending, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline
/PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit…
Expanding Safe Access to Peptides
Hims & Hers co-founder and CEO Andrew Dudum on the Department of Health and Human Services (HHS) announcement to expand…
Hims & Hers Health gains on peptide compounding news: Can HIMS continue its rally?
Hims & Hers Health trades at $29.32 today, up 4.98% after positive regulatory news. See the latest stock move and…
Hims & Hers Health (HIMS) Faces A Valuation Test After Peptide Rule Shift
The catalyst for renewed attention on Hims & Hers Health (HIMS) is a temporary shift in U.S. peptide rules, which…
Hims & Hers Health, Inc. (HIMS) Seasonal returns chart
Hims & Hers Health, Inc. (HIMS) seasonal returns chart provides the mean and median returns by month to inform your…
HIMS Deadline in 5 Days: Hims & Hers Health, Inc. Class Action Lawsuit Seeks Recovery for Investors; November 2, 2026 Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud…
Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide Compounding
A nice opening, but the margin question hasn’t gone anywhere…
Hims & Hers rises as U.S. to allow compounding of six peptides
Hims & Hers (HIMS) stock rose after the U.S. announced plans to allow compounding pharmacies to manufacture six peptides temporarily.…